ARTICLE | Clinical News
MM-121: Phase I data
October 15, 2012 7:00 AM UTC
An open-label, dose-escalation, U.S. Phase I trial in 28 patients with platinum-resistant gynecological cancers or HER2 non-overexpressing breast cancer showed that MM-121 plus paclitaxel produced a ...